Veru to present at the oppenheimer 34th annual healthcare life sciences conference

Miami, fl, jan. 31, 2024 (globe newswire) -- veru inc. (nasdaq: veru), a late clinical stage biopharmaceutical company focused on developing novel medicines for obesity, oncology, and viral induced acute respiratory distress syndrome (ards), today announced that mitchell steiner, m.d., chairman, president and chief executive officer of veru, will present an update of veru's phase 2b clinical program of enobosarm to augment fat loss and to avoid muscle loss when combined with glp-1 drugs for weight loss at the upcoming virtual oppenheimer 34th annual healthcare life sciences conference on wednesday, february 14, 2024 at 12:40 pm – 1:10 pm et.
VERU Ratings Summary
VERU Quant Ranking